Compare Stocks: MGEN, MGNX, ALEC, and IFRX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALEC Alector	$2.08 +3.0%	$2.08	$1.09 ▼ $3.40	$232.25M	0.62	6.62 million shs	3.10 million shs
IFRX InflaRx	$1.60 +4.6%	$1.99	$0.80 ▼ $2.95	$235.79M	2.59	521,799 shs	740,708 shs
MGEN Miragen Therapeutics	$14.47 +3.7%	$17.69	$4.66 ▼ $34.05	$56.55M	1.66	134,027 shs	4.59 million shs
MGNX MacroGenics	$3.74 +5.4%	$4.00	$1.29 ▼ $5.08	$238.24M	1.2	620,615 shs	418,440 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALEC Alector	0.00%	+14.92%	-2.80%	+29.19%	-32.47%
IFRX InflaRx	0.00%	-6.98%	-21.95%	-21.95%	+8.84%
MGEN Miragen Therapeutics	0.00%	0.00%	0.00%	0.00%	-31.10%
MGNX MacroGenics	0.00%	+4.47%	-5.79%	-13.63%	+110.11%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALEC Alector	$2.08 +3.0%	$2.08	$1.09 ▼ $3.40	$232.25M	0.62	6.62 million shs	3.10 million shs
IFRX InflaRx	$1.60 +4.6%	$1.99	$0.80 ▼ $2.95	$235.79M	2.59	521,799 shs	740,708 shs
MGEN Miragen Therapeutics	$14.47 +3.7%	$17.69	$4.66 ▼ $34.05	$56.55M	1.66	134,027 shs	4.59 million shs
MGNX MacroGenics	$3.74 +5.4%	$4.00	$1.29 ▼ $5.08	$238.24M	1.2	620,615 shs	418,440 shs

The 10 Best High-Yield Dividend Stocks for 2026

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALEC Alector	0.00%	+14.92%	-2.80%	+29.19%	-32.47%
IFRX InflaRx	0.00%	-6.98%	-21.95%	-21.95%	+8.84%
MGEN Miragen Therapeutics	0.00%	0.00%	0.00%	0.00%	-31.10%
MGNX MacroGenics	0.00%	+4.47%	-5.79%	-13.63%	+110.11%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALEC Alector	2.11	Hold	$3.40	63.46% Upside
IFRX InflaRx	2.67	Moderate Buy	$7.43	364.29% Upside
MGEN Miragen Therapeutics	0.00	N/A	N/A	N/A
MGNX MacroGenics	2.17	Hold	$6.33	69.34% Upside

Current Analyst Ratings Breakdown

Latest MGEN, MGNX, ALEC, and IFRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/6/2026	ALEC Alector	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Underweight	$2.00 ➝ $3.00
10/6/2026	ALEC Alector	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral	$1.50
9/21/2026	IFRX InflaRx	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/14/2026	IFRX InflaRx	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$8.00
8/25/2026	IFRX InflaRx	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/17/2026	MGNX MacroGenics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$9.00 ➝ $11.00
8/13/2026	ALEC Alector	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/7/2026	IFRX InflaRx	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$4.00 ➝ $6.00
8/5/2026	MGNX MacroGenics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/31/2026	ALEC Alector	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/27/2026	IFRX InflaRx	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy

(Data available from 10/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALEC Alector	$21.05M	11.03	N/A	N/A	$0.28 per share	7.43
IFRX InflaRx	$30K	7,859.73	N/A	N/A	$0.65 per share	2.46
MGEN Miragen Therapeutics	$4.46M	12.68	N/A	N/A	$6.78 per share	2.13
MGNX MacroGenics	$149.50M	1.59	N/A	N/A	$0.88 per share	4.25

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALEC Alector	-$142.93M	-$1.10	N/A	N/A	N/A	-850.13%	-531.03%	-44.00%	11/5/2026 (Estimated)
IFRX InflaRx	-$51.63M	-$0.58	N/A	N/A	N/A	N/A	-53.56%	-43.02%	11/9/2026 (Estimated)
MGEN Miragen Therapeutics	-$41.87M	-$20.09	N/A	N/A	N/A	-1,393.50%	-141.66%	-88.74%	N/A
MGNX MacroGenics	-$74.62M	-$0.22	N/A	N/A	N/A	-8.70%	-109.26%	-18.70%	11/11/2026 (Estimated)

Latest MGEN, MGNX, ALEC, and IFRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	ALEC Alector	-$0.23	N/A	N/A	N/A	$2.38 million	N/A
8/13/2026	Q2 2026	MGNX MacroGenics	-$0.0779	$0.31	+$0.3879	$0.31	$59.14 million	$32.83 million
8/7/2026	Q2 2026	IFRX InflaRx	-$0.0666	-$0.11	-$0.0434	-$0.10	$0.01 million	N/A
8/6/2026	Q2 2026	ALEC Alector	-$0.2286	-$0.21	+$0.0186	-$0.21	$1.71 million	$3.32 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALEC Alector	N/A	N/A	N/A	N/A	N/A
IFRX InflaRx	N/A	N/A	N/A	N/A	N/A
MGEN Miragen Therapeutics	N/A	N/A	N/A	N/A	N/A
MGNX MacroGenics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALEC Alector	0.80	5.26	5.26
IFRX InflaRx	N/A	8.22	8.22
MGEN Miragen Therapeutics	0.20	4.23	4.23
MGNX MacroGenics	N/A	2.96	2.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALEC Alector	85.83%
IFRX InflaRx	42.39%
MGEN Miragen Therapeutics	N/A
MGNX MacroGenics	96.89%

Insider Ownership

Company	Insider Ownership
ALEC Alector	8.30%
IFRX InflaRx	16.30%
MGEN Miragen Therapeutics	1.10%
MGNX MacroGenics	13.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALEC Alector	103	111.66 million	102.39 million	Optionable
IFRX InflaRx	65	147.37 million	123.35 million	Optionable
MGEN Miragen Therapeutics	45	3.91 million	N/A	Not Optionable
MGNX MacroGenics	293	63.70 million	55.04 million	Optionable

MGEN, MGNX, ALEC, and IFRX Headlines

Recent News About These Companies

Financial Review: Madrigal Pharmaceuticals (NASDAQ:MDGL) & MacroGenics (NASDAQ:MGNX)

October 10 at 4:29 AM | americanbankingnews.com

Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year?

October 9 at 10:41 AM | zacks.com

MacroGenics insider exercises 8,000 options for MacroGenics stock

October 9 at 7:01 AM | ad-hoc-news.deA

MacroGenics stock fell 2.47 percent on October 7 with pipeline data ahead

October 7, 2026 | ad-hoc-news.deA

MacroGenics stock faces October data after a Q2 revenue miss

October 5, 2026 | ad-hoc-news.deA

MacroGenics (NASDAQ:MGNX) & Keros Therapeutics (NASDAQ:KROS) Head-To-Head Survey

October 5, 2026 | americanbankingnews.com

2,488,252 Shares in MacroGenics, Inc. $MGNX Acquired by Bank of America Corp DE

September 26, 2026 | marketbeat.com

MacroGenics stock holds at USD 4.12 as cash strength stands out

September 23, 2026 | ad-hoc-news.deA

MacroGenics, Inc. (NASDAQ:MGNX) Receives Consensus Recommendation of "Hold" from Analysts

September 22, 2026 | marketbeat.com

MacroGenics stock edges lower as biotech analysts highlight risk and upside

September 19, 2026 | ad-hoc-news.deA

MacroGenics consensus price target rises 12% to $9.52

September 14, 2026 | msn.com

MacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

September 9, 2026 | globenewswire.com

MacroGenics: Inexpensive ADC/TCE Biotech With Multiple Catalysts Ahead

September 9, 2026 | seekingalpha.com

MacroGenics (NASDAQ:MGNX) VP Sells $129,085.75 in Stock

August 21, 2026 | insidertrades.com

Is MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year?

August 20, 2026 | zacks.com

MacroGenics (MGNX) Reports Q2 Loss, Lags Revenue Estimates

August 13, 2026 | zacks.com

MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position

August 13, 2026 | globenewswire.com

MacroGenics, Inc.: MacroGenics Announces Achievement of $10 Million Milestone Following Gilead's Exercise of Option to License Preclinical Bispecific Program

August 12, 2026 | finanznachrichten.de

MacroGenics Announces Achievement of $10 Million Milestone Following Gilead's Exercise of Option to License Preclinical Bispecific Program

August 11, 2026 | globenewswire.com

MacroGenics: Whipsaws On Clinical Data, But The Big Picture Is Still Important

July 27, 2026 | seekingalpha.com

MacroGenics Advances MGC026 in Phase 1 Oncology Trial

July 25, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

MGEN, MGNX, ALEC, and IFRX Company Descriptions

Alector NASDAQ:ALEC

$2.08 +0.06 (+2.97%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$2.07 -0.01 (-0.48%)

As of 10/9/2026 07:52 PM Eastern

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

InflaRx NASDAQ:IFRX

$1.60 +0.07 (+4.58%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$1.60 -0.01 (-0.31%)

As of 10/9/2026 07:30 PM Eastern

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

Miragen Therapeutics NASDAQ:MGEN

Miragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high-unmet medical need. Its four lead product candidates include cobomarsen, an inhibitor of miR-155 for treating various blood cancers, such as cutaneous T-cell lymphoma, adult T-cell lymphoma/leukemia, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia; Remlarsen, a replacement for miR-29, a microRNA that is found at abnormally low levels in various pathological fibrotic conditions, including cutaneous and ocular fibrosis, which is in Phase II clinical trial; MRG-229, which is in preclinical trial for the treatment of idiopathic pulmonary fibrosis; and MRG- 110, an inhibitor of miR-92, a microRNA expressed in endothelial cells, which has completed two Phase I clinical trial for the treatment of heart failure, wound healing, and other ischemic disease in the United States and Japan. Miragen Therapeutics, Inc. was founded in 2006 and is based in Boulder, Colorado.

MacroGenics NASDAQ:MGNX

$3.74 +0.19 (+5.35%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$3.74 +0.00 (+0.13%)

As of 10/9/2026 07:35 PM Eastern

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MGEN, MGNX, ALEC, and IFRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MGEN, MGNX, ALEC, and IFRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MGEN, MGNX, ALEC, and IFRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

MGEN, MGNX, ALEC, and IFRX Company Descriptions

Alector NASDAQ:ALEC

InflaRx NASDAQ:IFRX

Miragen Therapeutics NASDAQ:MGEN

MacroGenics NASDAQ:MGNX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MGEN, MGNX, ALEC, and IFRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MGEN, MGNX, ALEC, and IFRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MGEN, MGNX, ALEC, and IFRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

MGEN, MGNX, ALEC, and IFRX Company Descriptions

Alector NASDAQ:ALEC

InflaRx NASDAQ:IFRX

Miragen Therapeutics NASDAQ:MGEN

MacroGenics NASDAQ:MGNX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools